Abstract: P-chiral bisphospholane ligands and methods for their preparation are described. Use of metal/P-chiral bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: Free perfluorosulfonylmethide compounds and metal salts thereof show strong catalytic activity in carbon-carbon bond formation reactions, in amounts as low as 0.1 mole %. Fluorous media may be used, especially biphasic fluorous media enabling ready recycling of the catalyst. The formula thereof is: M[C(SO2R1)3−(m+q)(SO2R2)m(SO2R3)q]x where M is H, Sc, Y, La, Ce, Pr, Nd, Sm Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Zr, Hf, Th, Nb, Ta, U, Bi, Al, Ga, In or Tl, x is the common oxidation state of a said metal M, R1, R2 and R3 are perfluorinated or polyfluoronated hydrocarbon, ether or amine moieties or mixtures thereof and m+q=0, 1, 2 or 3 (m and q being zero or integers).

Abstract: An intramolecularly-quenched, near infrared fluorescence probe that emits substantial fluorescence only after interaction with a target tissue (i.e., activation) is disclosed. The probe includes a polymeric backbone and a plurality of near infrared fluorochromes covalently linked to the backbone at fluorescence-quenching interaction-permissive positions separable by enzymatic cleavage at fluorescence activation sites. The probe optionally includes protective chains or fluorochrome spacers, or both. Also disclosed are methods of using the intramolecularly-quenched, near infrared fluorescence probes for in vivo optical imaging.

Abstract: Compounds and metal complexes comprising a polycyclic, fused ring ligand or inertly substituted derivative thereof having up to 60 atoms other than hydrogen, said ligand comprising at least: (1) a cyclopentadienyl ring, (2) a 6, 7, or 8 membered ring other than a 6-carbon aromatic ring, and (3) an aromatic ring, with the proviso that said 6, 7, or 8 membered ring (2), is fused to both the cyclopentadienyl ring (1), and the aromatic ring (3), polymerization catalysts, a process to prepare the novel compounds and complexes, and olefin polymerization processes using the same are disclosed.

Abstract: This invention relates to a composition of matter comprising the catalyst compound comprising a transition metal complexed with a facially coordinating tridentate bisamide ligand. The invention is also directed to a catalyst system or a supported catalyst system comprising this compound and an activator and to a process for using the catalyst system or supported catalyst system in a process for polymerizing olefin(s).

Abstract: A half-sandwich coordination complex, useful for the synthesis of triple-decker sandwich coordination compounds, is produced by reacting a precursor complex of the formula XM(R1)2 wherein X is a halogen, M is a metal, and R1 is an amide, with a free base porphyrinic macrocycle to produce said half-sandwich complex. The half-sandwich coordination complex can be used to make a triple-decker sandwich coordination compound by reacting a half-sandwich coordination complex as described above with a double-decker sandwich coordination compound.

Abstract: The present invention provides methods and compositions for imaging cell death in vivo, as well as methods and compositions for tumor radiotherapy.

Abstract: The present invention provides a non-metallocene catalyst comprising a complex having one or more ligands coordinated a transition metal. The catalyst contains substituents bonded to the transition metal through a heteroatom such as oxygen or sulfur. Furthermore, the complex includes a Group 3 to 10 transition or lanthanide metal and one or more anionic or neutral ligands in an amount that satisfies the valency of the metal such that the complex has a net zero charge. The present invention also discloses a method for preparing the catalyst and polymerizing olefins utilizing the catalyst of the present invention.

Abstract: Novel derivatives of metallotexaphyrins are prepared by modifying the apical ligands associated with the central metal component of a metallotexaphyrin.

Abstract: The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.

Abstract: There is provided a method of labeling a biomolecule with a transition metal or radiometal in a site specific manner to produce a diagnostic or therapeutic pharmaceutical compound by synthesizing a P2N2-bifunctional chelating agent intermediate, complexing the intermediate with a radio metal or a transition metal, and covalently linking the resulting metal-complexed bifunctional chelating agent with a biomolecule in a site specific manner. Also provided is a method of synthesizing the —PR2 containing biomolecules by synthesizing a P2N2-bifunctional chelating agent intermediate, complexing the intermediate with a radiometal or a transition metal, and covalently linking the resulting radio metal-complexed bifunctional chelating agent with a biomolecule in a site specific manner. There is provided a therapeutic or diagnostic agent comprising a —PR2 containing biomolecule.

Abstract: A class of metallocene compounds is disclosed having general formula (I) wherein Y is a moiety of formula (II) wherein A, B, and D, same or different from each other, are selected from an element of the groups 14 to 16 of the Periodic Table of the Elements (new IUPAC version), with the exclusion of nitrogen and oxygen; R1, R2, R3, R4 and R5 are hydrogen or hydrocarbon groups, Z is selected from a moiety of formula (II) as described above and from a moiety of formula (III) wherein R6, R7, R8 and R9, are hydrogen or hydrocarbon groups; L is a divalent bridging group; M is an atom of a transition metal selected from those belonging to group 3, 4, 5, 6 or to the lanthanide or actinide groups in the Periodic Table of the Elements (new IUPAC version), X, same or different, is hydrogen, a halogen, a R10, OR10, OSO2CF3, OCOR10, SR10, NR102 or PR102 group, wherein the substituents R10 are hydrogen or alkyl groups; p is an integer of from 1 to 3, being equal to the oxidation state of the metal M minus 2.

Abstract: A fluorescent material comprising an associate of a cyclic phenol sulfide selected from thiacarixarene, sulfinylated thiacarixarene and sulfonylated thiacarixarene represented by formula (1): 1

Abstract: Disclosed herein are compounds shown as Formula I: 1

Abstract: Metal complexes of metals of the scandium group with an azo compound which conforms to the formula (I) or to one of its tautomeric structures 1

Abstract: A porphyrin ring-fusion polymer which consists of two or more Zn(II)-porphyrin rings fused in a single direction and in which any two porphyrin rings adjacent to each other are fused by three covalent bonds, that is, one meso-meso carbon bond (i.e., one bond between meso-position carbon atoms) and two &bgr;-&bgr; carbon bonds (i.e., two bonds between &bgr;-position carbon atoms adjacent to the meso-position carbon atoms); a process for preparing the porphyrin ring-fusion polymer regioselectively by conducing the fusion reaction in an aromatic hydrocarbon solvent in the presence of a quinoline and Lewis acid containing rare earth element under reflux; and fused-ring porphyrin compound obtained by subjecting the porphyrin ring-fusion polymer to demetallization or replacement of the Zn atoms by other metal atoms.

Abstract: The present invention provides a method for testing an agent for its potential to inhibit heparanase catalytic activity, comprising the steps of: interacting immobilized heparanase substrate binding protein on a solid support with labeled heparanase substrate to provide immobilized labeled heparanase substrate, interacting a heparanase enzyme solution with the immobilized labeled heparanase substrate in the presence of the agent, and detecting the presence or absence of label in the solution remote from the solid support. The labeled heparanase substrate may be bound to an immobilization bridge which binds to immobilized molecules on a solid support, to provide bridge-immobilized labeled heparanase substrate.

Abstract: N-substituted 3-hydroxy-4-pyridinones and metal chelates, methods of preparing N-substituted 3-hydroxy-4-pyridinones and metal chelates, and pharmaceutical compositions containing new N-substituted 3-hydroxy-4-pyridinones and/or their metal chelates. Use of N-substituted 3-hydroxy-4-pyridinones and their metal chelates as pharmaceutical agents for the treatment of diseases, such as parasitic and viral infections, conditions associated with inflammation and infection, and conditions mediated by cell-proliferation or collagen formation.

Abstract: New polycyclic cyclopentadiene compounds having the formula (II) wherein the various substituents and symbols R1, R2, R3, R4, R5, R6, R7, Z1 and Z2 and “n” have the meaning specified in the description. These compounds can form metallocene complexes with transition metals, which have shown unusual properties in the (co)polymerization of ethylene and alpha-olefins in general.

Abstract: This invention provides an easily synthesized trivalent organic lanthanoid complex which can be used as a polymerization catalyst for (meth) acrylic monomers.

Abstract: Compounds and metal complexes comprising a polycyclic, fused ring ligand or inertly substituted derivative thereof having up to 60 atoms other than hydrogen, said ligand comprising at least: (1) a cyclopentadienyl ring, (2) a 6, 7, or 8 membered ring other than a 6-carbon aromatic ring, and (3) an aromatic ring, with the proviso that said 6, 7, or 8 membered ring (2), is fused to both the cyclopentadienyl ring (1), and the aromatic ring (3), polymerization catalysts, a process to prepare the novel compounds and complexes, and olefin polymerization processes using the same are disclosed.

Abstract: The present invention relates to novel complexes of (transition) metals containing ligands having phosphorus centers supporting a carbene atom or heteroalkane radical bonded to the (transition) metal.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: The present invention is generally directed to luminescent lanthanide compounds with phosphine oxide, phosphine oxide-sulfide, pyridine N-oxide, and phosphine oxide-pyridine N-oxide ligands. It also relates to electronic devices in which the active layer includes a lanthanide complex.

Abstract: The invention provides metallocene catalyst systems for the controlled polymerization of alkenes to a wide variety of polyolefins and olefin coplymers. Catalyst systems are provided that specifically produce isotactic, syndiotactic and steroblock polyolefins. The type of polymer produced can be controlled by varying the catalyst system, specifically by varying the ligand substituents. Such catalyst systems are particularly useful for the polymerization of polypropylene to give elastomeric polypropylenes. The invention also provides novel elastomeric polypropylene polymers characterized by dyad (m) tacticities of about 55% to about 65%, pentad (mmmm) tacticities of about 25% to about 35%, molecular weights (MW)in the range of about 50,000 to about 2,000,000, and have mmrm+rrmr peak is less than about 5%.

Abstract: Process for the synthesis of polyurethane derivatives from aromatic polyamine compounds. The method involves the reaction of an aromatic polyamine compound with CO and O2 in the presence of a catalyst comprising a Group VIII or lanthanide metal on a solid support and a halogenide promoter.

Abstract: There is provided a complex having a specified chemical structure and an asymmetric catalyst using such a complex. Further, an epoxidation of amine or ketone is enantioselectively conducted by using such an asymmetric catalyst.

Abstract: Certain complexes containing ligands having a phosphino group, amino group or an imino group, and a second functional group such as amide, ester or ketone, when complexed to transition metals, catalyze the (co)polymerization of olefinic compounds such as ethylene, &agr;-olefins and/or acrylates. A newly recognized class of ligands for making copolymer containing polar monomers using late transition metal complexes is described.

Abstract: Heparinoid derivatives comprising a chelating agent which is covalently bonded to the heparinoid, and a paramagnetic metal cation from the series of transition metals Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Mo, Ru or of the lanthanides, are suitable for producing medicaments both for therapy and for diagnostic purposes, for localizing the dose employed, and for monitoring the result of treatment of disorders such as thrombosis and osteoarthrosis.

Abstract: Catalyst precursor compounds having both (i) a polydentate ligand which comprises a cyclic moiety as well as a heteroatom and (ii) a protected hydride/hydrocarbyl ligand bonded to a metal atom, as well as olefin polymerization catalyst systems based thereupon, polymerization processes using such catalyst systems and polymers produced thereby.

Abstract: A phosphorescent light emitting material, the material is a complex compound comprises a beta-diketonate ligand, a sulfoxide ligand and a triple charge rare earth group metal ion, the phosphorescent light emitting material has a following structure: 1

Abstract: Fluorescent chelates of lanthanide, terbium, europium and dysprosium with tetraazamacrocyclic compounds are discussed which can be used as fluorescent in vitro or in vivo diagnostic agents. These chelates are tissue specific imaging agents for soft tissue cancers.

Abstract: The present invention provides methods of making porphyrins and related compounds such as chlorins by condensing suitable starting materials (e.g., a dipyrromethane-dicarbinol plus dipyrromethane) in a polar solvent in the presence of a Lewis acid. The reactions are preferably carried out in a manner that minimizes rearrangement of the reaction product.

Abstract: This invention is directed to novel catalysts the structure and activity of which can be controlled to produce a wide range of alpha olefin polymers and co-polymers, and preferably for the production of stereoblock poly alpha olefins comprising a wide range of preselected amorphous and crystalline segments for precise control of the physical properties thereof, principally elastomeric thermoplastic properties. More specifically, this invention is directed to novel catalysts and catalysts systems for producing stereoblock polypropylene comprising alternating isotactic and atactic diastereosequences, which result in a wide range of elastomeric properties. The amount and numbers of crystalline sections, the isotactic pentad content, the number and length of intermediate atactic chains and overall molecular weight are all controllable by the steric structure of the catalysts and the process conditions.

Abstract: The present invention covers halogenated derivatives of boronated porphyrins containing multiple carborane cages having the formula which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron- capture therapy and photodynamic therapy. The present invention also covers methods for using these halogenated derivatives of boronated porphyrins in tumor imaging and cancer treatment.

Abstract: This invention relates to new macrocyclic chelants and metal chelates thereof, methods of preparing the chelants and metal chelates, and pharmaceutical compositions comprising the macrocyclic chelants and metal chelates. This invention relates particularly to the use of the new metal chelates as contrast agents in X-ray or CT, MRI imaging, and radiopharmaceuticals for the diagnosis of cardiovascular disorders, infectious disease and cancer. This invention also relates to new bifunctional chelants (BFCs) for attaching diagnostic metals and therapeutic isotopes to target-specific biomolecules such as proteins, peptides, peptidomimetics, and non-peptide receptor ligands. In addition, the macrocyclic chelants are useful for heavy metal detoxification.

Abstract: A half-sandwich coordination complex, useful for the synthesis of triple-decker sandwich coordination compounds, is produced by reacting a precursor complex of the formula XM(R1)2 wherein X is a halogen, M is a metal, and R1 is an amide, with a free base porphyrinic macrocycle to produce said half-sandwich complex. The half-sandwich coordination complex can be used to make a triple-decker sandwich coordination compound by reacting a half-sandwich coordination complex as described above with a double-decker sandwich coordination compound.

Abstract: A europium-ammonium tetra chelate compound, composition, and method for making the compound according to the formula NH4+Eu3+[X]4.H2O, where X is a bidentate ligand is provided. The bidentate ligand may be diketone, and includes thenoyltrifluoroactonate, benzoyltrifluoroacetonate, and napthyltrifluoroacetonate ligands. The compound is invisible under ordinary light conditions, exhibits fluorescence upon exposure to UV light, and is soluble in alcohol and alcohol/water based solutions. The compound may be used as a dye in ink formulations, among other applications.

Abstract: The present invention covers radiosensitizers containing as an active ingredient halogenated derivatives of boronated porphyrins containing multiple carborane cages which selectively accumulate in neoplastic tissue within the irradiation volume and thus can be used in cancer therapies including, but not limited to, boron neutron-capture therapy and photodynamic therapy. The present invention also covers methods for using these radiosensitizers in tumor imaging and cancer treatment.

Abstract: Novel cyclic polyamine compounds of the form 1

Abstract: The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration <10−3 mol/l, a hydrodynamic micelle diameter (2 Rh)>1 nm and a proton relaxivity in plasma (R1)>10 l/mmol·s) as contrast media in MR imaging for visualization of plaque, lymph nodes, infarcted and necrotic tissue and for independent visualization of necrotic tissue and tumor tissue.

Abstract: The present invention is directed, in part, to coordination complexes for detecting analytes, and methods of making and using the same.

Abstract: A lanthanum complex of formula (I) having a low evaporation temperature can be used as a useful precursor for MOCVD of a BLT thin layer on semiconductor devices.

Abstract: The present invention relates to novel complexes of (transition) metals containing ligands having phosphorus centers supporting a carbene atom or heteroalkane radical bonded to the (transition) metal.

Abstract: A compound comprising a chemical combination of a photodynamic tetra-pyrrolic compound with a plurality of radionuclide element atoms such that the compound may be used to enhance MR imaging and also be used as a photodynamic compound for use in photodynamic therapy to treat hyperproliferative tissue.

Abstract: The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.

Abstract: The invention provides true La(OiPr)3 preferable as a starting material for an asymmetric synthesis catalyst and a process for producing the same. In this process, anhydrous lanthanum chloride LaCl3 is reacted with potassium isopropoxide K(OiPr) in a mixed solvent of isopropanol and toluene, then the isopropanol is distilled away to replace all the solvent by toluene, then the reaction solution is left, decanted and filtered to give a transparent filtrate, and the solvent is distilled away from the filtrate which is then vacuum-dried under heating, whereby high-purity La(OiPr)3 is obtained in 77% yield. In this high-purity La(OiPr)3, the La content is 97 to 103% of the theoretical content, impurity K is 0.3% or less, (Li+Na) is 0.01% or less, Cl is 0.2% or less, and the degree of association thereof is 5.5 to 6.5.

Abstract: New ligands having a backbone comprised of NCCX can be combined with a metal or metal precursor compound or formed into a metal-ligand complex to catalyze a number of different chemical transformations, including polymerization.

Abstract: Compounds of formula (I) and (II) wherein the R, R1, R2, R3 and R4 groups have the meanings defined in the disclosure, are useful chelants for metal ions. The complexes of compounds (I) and (II) with paramagnetic ions are useful as contrast agents for M.R.I. imaging.